GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » Shiller PE Ratio

Rosetta Genomics (Rosetta Genomics) Shiller PE Ratio : (As of May. 23, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Rosetta Genomics Shiller PE Ratio Historical Data

The historical data trend for Rosetta Genomics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Shiller PE Ratio Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Rosetta Genomics Quarterly Data
Dec10 Mar11 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rosetta Genomics's Shiller PE Ratio

For the Diagnostics & Research subindustry, Rosetta Genomics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rosetta Genomics's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Shiller PE Ratio falls into.



Rosetta Genomics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Rosetta Genomics's E10 for the quarter that ended in Jun. 2017 is calculated as:

For example, Rosetta Genomics's adjusted earnings per share data for the three months ended in Jun. 2017 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2017 (Change)*Current CPI (Jun. 2017)
=-0.81/103.3491*103.3491
=-0.810

Current CPI (Jun. 2017) = 103.3491.

Rosetta Genomics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200512 -525.599 83.032 -654.208
200603 -518.399 84.298 -635.557
200606 -518.399 85.606 -625.847
200609 -518.399 85.606 -625.847
200612 -590.399 85.142 -716.656
200703 -165.600 86.640 -197.537
200706 -136.800 87.906 -160.833
200709 -129.600 87.964 -152.267
200712 -525.599 88.616 -612.981
200803 -237.600 90.090 -272.570
200806 -223.200 92.320 -249.864
200809 -172.800 92.307 -193.471
200812 64.800 88.697 75.504
200903 -216.000 89.744 -248.745
200906 -288.000 91.003 -327.071
200909 -172.800 91.120 -195.992
200912 -201.600 91.111 -228.679
201003 -165.600 91.821 -186.391
201006 -194.400 91.962 -218.472
201009 -144.000 92.162 -161.480
201012 -153.003 92.474 -170.996
201103 -50.400 94.283 -55.246
201106 -61.081 95.235 -66.285
201112 -17.400 95.213 -18.887
201206 -64.010 96.819 -68.327
201212 -0.505 96.871 -0.539
201306 -0.680 98.518 -0.713
201312 -0.662 98.326 -0.696
201406 193.680 100.560 199.053
201409 -3.480 100.428 -3.581
201412 -4.110 99.070 -4.288
201503 -3.600 99.621 -3.735
201506 -2.400 100.684 -2.464
201509 -3.240 100.392 -3.335
201512 -4.670 99.792 -4.836
201603 -2.400 100.470 -2.469
201606 -1.950 101.688 -1.982
201609 -2.280 101.861 -2.313
201612 -2.710 101.863 -2.750
201706 -0.810 103.349 -0.810

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Rosetta Genomics  (OTCPK:ROSGQ) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Rosetta Genomics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rosetta Genomics (Rosetta Genomics) Business Description

Traded in Other Exchanges
N/A
Address
10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Executives
Sabby Management, Llc 10 percent owner 115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd. 10 percent owner C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458